Genelux (GNLX) Accounts Payables (2022 - 2026)

Genelux (GNLX) posted quarterly Accounts Payables of $6.1 million for Q1 2026, up 39.86% quarter-over-quarter from $4.4 million in Q4 2025.

Genelux (GNLX) Accounts Payables (2022 - 2026) Analysis & Trends

Genelux's Accounts Payables history runs 5 years deep, the most recent figure standing at $6.1 million for Q1 2026.

In Q1 2026, Accounts Payables changed N/A year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $4.4 million, down 21.76% from the prior year.
Accounts Payables for Q1 2026 stood at $6.1 million, up from $4.4 million in the prior quarter.
The five-year high for Accounts Payables was $6.8 million in Q4 2022, with the low at $3.8 million in Q4 2023.
The 5-year median for Accounts Payables is $4.8 million (2024), against an average of $5.0 million.
The sharpest annual moves came in 2023 and 2024: Accounts Payables sank 44.15% in 2023, then soared 47.2% in 2024.
Genelux's Accounts Payables stood at $6.8 million in 2022, then sank by 44.15% to $3.8 million in 2023, then soared by 47.2% to $5.6 million in 2024, then dropped by 21.76% to $4.4 million in 2025, then soared by 39.86% to $6.1 million in 2026.
Business Quant data shows GNLX's Accounts Payables at $6.1 million in Q1 2026, $4.4 million in Q4 2025, and $4.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	108.02 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	622.65 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	428.93 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	35.57 Mn
10	Genelux	119.87 Mn	119.87 Mn	-	6.10 Mn

Download Data